HumanCD4+TCell.ImagecourtesyofNIAID. 

Tcellsareregulatorsoftheimmunesystem.CD4+TcellsarealsoknownashelperTcellsbecausetheyactonothercellsoftheimmunesystemtopromotevariousaspectsoftheimmuneresponse,includingimmunoglobulinisotypeswitchingandaffinitymaturationoftheantibodyresponse,macrophageactivationandenhancedactivityofnaturalkillercellsandcytotoxicTcells.

CellsYouCanCountontoPerform

LonzaCD4+TCellsareisolatedfromperipheralbloodofhealthydonors.Briefly,mononuclearcells(MNCsorPBMCs)areisolatedfromapheresisderivedperipheralbloodandarefurtherpurifiedviaimmunomagneticselectiondirectedagainstCD4.

CryopreservedCD4+Tcellsareguaranteed≥90%pureforCD4+Tcells,asassessedbyflowcytometry.Theyareguaranteedtocontain≥10millionviablecellspervial.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.

Cellsareavailablefrommultipledonors.PleasecontactCustomerServicefordetailsonavailableinventoryanddonordemographiccharacteristics(age,gender,andethnicity).

ChoicesinCellTypeandTissueSource

Hematopoieticandimmuneresearchrequirescellsfromdifferentdonorsandtissuesources.That"swhyLonzaoffersmanydifferentperipheralbloodcelltypes.Ifyouneeddifferentcelltypesfromthesamedonor,youcaneitherisolatefromLonzacryopreservedPBMCsorcontactCustomerServicetoinquireaboutcellsmatchedfromthesamedonor.

Inaddition,ifyouareinterestedinmorenaiveTcells,unprocessedbonemarrow,autologousbonemarrowandwholebloodfromthesamedonor,bonemarrowCD34+cells,orcordbloodCD34+cellsmightbegoodsolutions.

SupportedbyLonzaMedia

LGM-3™LymphocyteGrowthMediumisrecommendedforoptimalperformance.PleasecontactScientificSupportforthawingandculturingguidance.

LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。